- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00972114
CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy
Coronary Artery Bypass Graft Surgery Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Patients With Ischemic Cardiomyopathy: a Prospective Randomized Controlled Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a phase I/II, randomized controlled trial to evaluate the use of CABG combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty for patients with ischemic cardiomyopathy. The study hypothesis is that the combined surgical technique to perform pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty as adjunct to CABG, is safe to patients with severe ischemic heart failure and can improve regional myocardial perfusion contractility, which resulting in improved systolic and diastolic left ventricular function.
The primary object of this study will be to evaluate the safety and efficacy of this novel combined surgical technique. The efficacy will be assessed changes in left ventricular ejection fraction by MRI. The secondary endpoint of the study is to assess the effects of this novel combined surgical technique on cardiac contractile function and functional outcome. The effects will be assessed on the basis of clinical status and imaging rests in 6 month follow-up after enrollment. A maximum of 60 patients between 20 and 70 years will be enrolled in the study. These participants will be randomized to receive CABG, pedicled omentum graft combined CABG, or pedicled omentum graft autologous atrial tissue patch cardiomyoplasty combined CABG. The objective evaluations will be performed at baseline and during 6 months follow-up.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100037
- Recruiting
- China National Center for Cardiovascular Diseases, Cardiovascular Institute & Fuwai Hospital
-
Contact:
- Jianfeng Hou, M.D., Ph.D.
- Phone Number: +86 10 88398359
- Email: hjf2006111@163.com
-
Beijing, China, 100037
- Not yet recruiting
- Institute of cardiovascular diseases & Fuwai hospital
-
Principal Investigator:
- shengshou hu, MD
-
Contact:
- Shengshou Hu, MD
- Phone Number: 0086-10-8839-8359
- Email: shengshouhu@yahoo.com
-
Contact:
- Jianfeng Hou, MD, PhD
- Phone Number: 0086-10-8839-8359
- Email: hjf2006111@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female;
- 20-70 years old;
- Ability to give informed consent;
- Documented severe coronary heart disease, defined as at least 70% luminal diameter narrowing of at least three major coronary artery, suited to CABG;
- Left ventricular dysfunction (LVEF) less than or equal to 35%, measured by MRI or less than or equal to 45%, measured by echocardiogram;
- Presence of reversibility, as identified by single photon emission computed tomography (SPECT) isotope protocol;
- At least 3 months since last episode of myocardial infarction;
- Without a history of abdominal operation and severe abdominal diseases;
- Negative pregnancy test (in women with childbearing potential.
Exclusion Criteria:
- Pregnant or lactating;
- A history of malignancy in the last 5 years excluding basal cell carcinoma, that has been surgically removed, with proof of surgical clean margins;
- a history of abdominal operation or severe abdominal diseases;
- Positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- Any condition requiring immunosuppressive medication;
- Bleeding diathesis, defined as an international normalized ratio of at least 2.0 in the absence of warfarin therapy;
- Hepatic dysfunction, as defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal range prior to study entry;
- Chronic renal insufficiency, defined as a serum creatinine level greater than 2.5 mg/dL or requiring dialysis;
- Leukocytes less than 4,000/µL or exceeding 10,000/µL;
- Platelets less than 100,000/µL;
- Hemoglobin less than 10 g/dL;
- Chronic atrial fibrillation;
- Less than 3 months since last episode of cerebral infarction;
- Implantable cardioverter-defibrillator shock within 30 days of baseline consent, and within 30 days of randomization;
- Presence of ventricular tachycardia lasting 30 seconds or more on 24-hour Holter monitor or electrocardiogram (ECG) performed during screening period;
- Patients for whom it is impossible to perform both cardiac MRI;
- Enrolled in an investigational device or drug study within the previous1 year;
- Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CABG combined cardiomyoplasty
Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
|
coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
Other Names:
|
Active Comparator: CABG combined pedicled omentum graft
Coronary artery bypass graft surgery combined pedicled omentum graft
|
Coronary artery bypass graft surgery combined pedicled omentum graft
|
Active Comparator: CABG alone
Coronary artery bypass graft surgery alone
|
Coronary artery bypass graft surgery alone
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of CABG combined pedicled omentum wrapped autologous atrial tissue transplantation.
Time Frame: 6 months
|
6 months
|
Changes in left ventricular ejection fraction (LVEF) by MRI.
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in LVEF by echocardiography.
Time Frame: 6 months
|
6 months
|
Changes in regional wall motion by MRI.
Time Frame: 6 months
|
6 months
|
Changes in regional wall motion by echocardiography.
Time Frame: 6 months
|
6 months
|
Changes in fixed perfusion defect(s) by single photon emission computed tomography.
Time Frame: 6 months
|
6 months
|
Clinical improvements, including change in 6 minutes walk test, as determined by multiple measures.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Investigators
- Study Director: Shengshou Hu, MD, National Center for Cardiovascular Diseases, China
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20090903
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on CABG combined cardiomyoplasty
-
Aarhus University Hospital SkejbyActive, not recruiting
-
China National Center for Cardiovascular DiseasesUnknownMyocardial Infarction | Coronary DiseaseChina
-
Meshalkin Research Institute of Pathology of CirculationUnknownMitral Valve InsufficiencyRussian Federation
-
Assiut UniversityRecruitingCAD - Coronary Artery DiseaseEgypt
-
Kuopio University HospitalTerminatedCoronary Artery Disease | Paroxysmal Atrial FibrillationFinland
-
St. Petersburg State Pavlov Medical UniversityRecruitingIschemic Heart Disease | Valve Heart Disease | Cardiac Procedure Complication | Defect SeptalRussian Federation
-
St. Petersburg State Pavlov Medical UniversityCompletedCoronary Artery Disease | CABG | Ischemic Heart Disease | Ischemic Reperfusion InjuryRussian Federation
-
Peking University Third HospitalNot yet recruitingMinimally Invasive Cardiac Surgery
-
Chinese Academy of SciencesThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...CompletedChronic Ischemic CardiomyopathyChina
-
University of AarhusUnknown